In the aim of exploring, at cellular level, the potentiality of CaSR as therapeutic target in the treatment of ADPKD, we considered, as valuable model system, ciPTEC obtained by immortalizing cells exfoliated from urine sediments of an ADPKD1 patient and ciPTEC obtained from healthy subject, knocked down for PKD1. This evidence concerns the gene PKD1 and autosomal dominant polycystic kidney disease.